We have developed a quantitative immunoblot method to measure the mole fraction of phospholamban (PLB) phosphorylated at Ser16 (X p ) in biological samples. In cardiomyocytes, PLB phosphorylation activates the sarcoplasmic reticulum calcium ATPase (SERCA), which reduces cytoplasmic Ca 2+ to relax the heart during diastole. Unphosphorylated PLB (uPLB) inhibits SERCA at low [Ca 2+ ] but phosphorylated PLB (pPLB) is less inhibitory, so myocardial physiology and pathology depend critically on X p . Current methods of X p determination by immunoblot provide moderate precision but poor accuracy. We have solved this problem using purified uPLB and pPLB standards produced by solid-phase peptide synthesis. In each assay, a pair of blots is performed with identical standards and unknowns using antibodies partially selective for uPLB and pPLB, respectively. When performed on mixtures of uPLB and pPLB, the assay measures both total PLB (tPLB) and X p with accuracy of 96% or better. We assayed pig cardiac sarcoplasmic reticulum (SR) and found that X p varied widely among four animals, from 0.08 to 0.38, but there was remarkably little variation in the ratios of X p /tPLB and uPLB/SERCA, suggesting that PLB phosphorylation is tuned to maintain homeostasis in SERCA regulation.
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Heart disease is the number one cause of mortality in the United States across all demographics, and the incidence is rising [1] . In cardiac sarcoplasmic reticulum (CSR), 1 phospholamban (PLB) phosphorylation acts as a molecular switch that activates SERCA (sarcoplasmic reticulum calcium ATPase). Active SERCA increases the calcium gradient across the sarcoplasmic reticulum (SR) during diastole [2] , accelerating relaxation and leading to a more forceful systolic contraction [3] . In the presence of unphosphorylated PLB (uPLB), SERCA is inhibited at submicromolar Ca 2+ , but b-adrenergic phosphorylation of PLB relieves this inhibition [4] [5] [6] [7] . Because SERCA activity is reduced in many instances of heart failure [8] [9] [10] , SERCA activation is a widely pursued goal for development of new therapies [11] . SERCA inhibition can be relieved by PLB phosphorylation, either at S16 by b-adrenergic activation of protein kinase A (PKA) [5, [12] [13] [14] or at T17 by calcium-dependent CaMII kinase [5] , but S16 phosphorylation is more important physiologically [15] [16] [17] [18] . In heart failure, phosphorylation of PLB may be reduced [9, 19] ; thus, it is desirable to increase the fraction of PLB that is phosphorylated (X p ) so that SERCA remains in its active state. PLB phosphorylation at S16 has been examined [2] , mimicked [20] [21] [22] [23] , and altered [10, 24] with the goal of developing therapies for heart failure, but the rational development and testing of these therapies is limited because PLB phosphorylation has not been measured accurately in biological systems. In the current study, we have solved this problem. Quantitation of X p in healthy versus failing myocardium is needed to establish correlations between PLB phosphorylation and cardiac function. These correlations will aid in development of prognostic indicators for differential diagnosis and in treatment of heart failure. For example, it has been shown that the R9C mutation in PLB leads to dilated cardiomyopathy [25] . This mutation hinders PLB binding to PKA, thereby decreasing PLB phosphorylation [26] , but this effect has not been defined in a quantitative measurement of X p , so its role in the disease mechanism remains unclear. Thus, X p measured from biopsied heart tissue (from animal models or patients) would provide crucial insight into the etiology and stages of heart failure and into the efficacies of therapeutic interventions.
There is one method that has been shown to measure X p accurately-quantitation of radioactivity after reaction of PLB with c-32 P-labeled ATP in the presence of PKA [27] . However, this method requires an accurate measurement of total PLB (tPLB), and it is limited in accuracy by the unknown basal phosphorylation state of PLB in most tissue samples. Thus, it has usually been used accurately only to analyze simple systems containing purified proteins [28] . It seems clear that a method involving quantitative immunoblots is the method of choice.
However, the properties of PLB have prevented accurate measurement of endogenous X p by previous immunoblot/densitometry 0003 techniques. Phosphorylation of PLB causes only a very slight shift in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and this shift is complicated by the multiple oligomeric forms of PLB that are observed [16, [27] [28] [29] . The ideal solution would be to use a pair of antibodies specific for phosphorylated PLB (pPLB) and uPLB, respectively. Fortunately, there is a commercially available antibody, designated Ab285, that is almost completely specific for pPLB [30] . Unfortunately, an antibody completely specific for uPLB has not been reported. Instead, commercial antibodies that bind uPLB cross-react with pPLB to varying degrees [16, [30] [31] [32] . For example, Ab1D11 [16, 30, 33] , AbA1 [34, 35] , Ab8A3 [31, 36] , and Ab2D12 [32] all bind both uPLB and pPLB with different degrees of selectivity [32] .
As we show below, antibodies that are completely specific for uPLB and pPLB are not strictly required for an accurate assay of X p . The most important requirement is a source of reliable standards, of known purity and concentration, for both uPLB and pPLB, so that the selectivity of antibodies can be quantitated on immunoblot. Primarily as a result of this lack of reliable standards, previous X p measurements have not been accurate.
We describe here a quantitative immunoblot method, involving the use of extremely pure synthetic standards for pPLB and uPLB, that measures both X p and tPLB with high accuracy and precision. In our approach, Western blots with identical standards and samples were performed, one labeled with Ab285 (almost completely specific for pPLB) and the other labeled with an antibody that is partially selective for uPLB. Following quantitative densitometry of the two immunoblots, a system of simultaneous equations is used to solve accurately for X p . Using mixtures of standard samples of uPLB and pPLB, the method is shown to be accurate (<5% error), and the method is then used to determine X p in samples from pig CSR.
Materials and methods

PLB standards
Solid-phase peptide synthesis and high-performance liquid chromatography (HPLC) purification were used to prepare porcine uPLB and pPLB standards with greater than 95% purity, as reported previously [37] [38] [39] [40] . PLB phosphorylation was accomplished by incorporation of p-Ser at position S16 as Fmoc-Ser(PO(OBzl)OH)-OH (EMD Chemicals) during peptide synthesis. Characterization was accomplished by mass spectrometry (matrix-assisted laser desorption/ionization time-of-flight, MALDI-TOF) and Edman protein sequencing. [37] [38] [39] [40] . PLB concentrations were measured with the BCA (bisinchoninic acid) assay (Pierce) [2, 38] and by amino acid analysis [38] .
Antibodies
Primary antibodies included Ab8A3 [31, 36] (a gift from Diana Bigelow, University of Kansas), Ab2D12 [32] (Abcam), AbA1 [34, 35] (Millipore), and Ab285 [41] (Merck). The first three were monoclonal mouse antibodies. Ab285 is a polyclonal rabbit antibody raised against a cytoplasmic fragment of pSer16-PLB. Fluorescent dye-conjugated secondary antibodies, used to visualize and quantitate immunoblots, were goat anti-mouse IR-800CW and goat anti-rabbit IR-680LT (LI-COR Biosciences).
Electrophoresis and Western blot
PLB was dissolved in Laemmli buffer (Bio-Rad) with 5% bmercaptoethanol, separated by SDS-PAGE on 10-20% Tris-tricine gels (Bio-Rad) at constant voltage (120 V) for 90 min at 25°C, and transferred to 0.45-lm Immobilon-FL polyvinylidene difluoride (PVDF) membranes (Millipore) in Towbin transfer buffer [42] for 50 min at constant current (300 mA), blocked overnight in pure Odyssey blocking buffer (LI-COR Biosciences), and rinsed for 1 min in doubly distilled H 2 O (ddH 2 O). Membranes were then incubated in primary antibody for 1 or 2 h (at concentrations recommended by the manufacturer) in blocking buffer consisting of 50% Odyssey blocking buffer and 50% Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBST). The primary antibody was washed from each blot three times for 15 min with TBST before adding secondary antibody at a dilution of 1:15,000 for 35 min. The membrane was then washed three times for 15 min with TBST, and the blots were stored in TBS. Proteins were detected and analyzed using LI-COR Odyssey with the 700-nm channel for the IR-680LT and the 800-nm channel for the 800CW (LI-COR Biosciences). Analysis by densitometry was accomplished with Odyssey software. The resolution was 169 lm, and the focus offset was 0.0 mm. Boxes were drawn around an area that encompassed all PLB bands (monomeric and oligomeric). The background was local, determined as the average or median of the intensities at the top and bottom of the box. The greatest linearity was obtained at a border width of 1 pixel.
SERCA quantitation
Pig CSR (10 mg) was dissolved in 1 ml of Laemmli sample buffer (Bio-Rad) containing 4% b-mercaptoethanol, loaded on a 4-20% Tris-HCl gel, and electrophoresed at 120 V for 90 min at 25°C. The gel was stained overnight with a solution containing 0.1% Coomassie Brilliant Blue, 40% methanol, 40% H 2 O, and 16% acetic acid and then was destained for 1 h in a solution containing 20% methanol, 5% isopropanol, 10% glacial acetic acid, and 65% H 2 O. The mass percentage of SERCA was calculated by densitometry with U SCANIT software.
Analysis of pig CSR
Pig CSR was prepared from the ventricle of a fresh pig heart (obtained from Lindenfelser's Meats, Monticello, MN, USA) and placed on ice within 10 s of sacrifice. One ventricle was dissected and homogenized in a blender with 250 ml of homogenization buffer containing 10 mM NaHCO 3 , 10 mM Tris-HCl (pH to 7.2 with KOH), 0.8 M benzamidine, 0.1 ug/mL aprotinin, 0.1 ug/mL leupeptin, 1 M phenylmethanesulfonyl fluoride (PMSF), and 0.1 ug/mL pepstatin. The homogenate was centrifuged at 4°C for 20 min at 11,000g (8500 rpm in a JA-14 rotor). The pellets were discarded, and the supernatant was filtered with cheesecloth. The volume of the supernatant was measured, and enough KCl was added to make a 0.6-M KCl solution, which was incubated at 4°C with gentle stirring for 1 h and then centrifuged at 4°C for 45 min at 100,000g (36,000 rpm in a Beckman 45Ti rotor). The pellet was resuspended using a hand homogenizer in 15 ml of sucrose buffer (10% sucrose, 20 mM Mops, and 1 mM NaN 3 [pH to 7.0] with KOH, 25 g/L aprotinin, 25 g/L leupeptin, 50 g/L benzamidine, 0.1 M PMSF, and 0.1 g/ml pepstatin A) and centrifuged again for 45 min at 100,000g. The pellet was resuspended in 1 ml of sucrose solution per 40 g of wet weight tissue with a hand homogenizer. The homogenate was then aliquoted into microfuge tubes ($0.5 ml/tube), flash frozen, and stored at À80°C. Electrophoresis and immunoblots were carried out as described above.
Derivation of fraction of PLB phosphorylated
The measured intensity for one band in a Western blot using antibody i is given by
where e ij is a proportionality constant (fluorescence units/ng PLB) that describes the slope of the standard curve for uPLB (j = u) or pPLB (j = p). The variable c k is the concentration of uPLB (k = u) or pPLB (k = p) in the unknown sample. As shown below, calculating c u and c p requires that one antibody (i = a) preferentially binds uPLB and the other antibody (i = b) preferentially binds pPLB, satisfying the condition e au > e ap and e bu < e bp ). Thus, for our system involving two species (uPLB and pPLB) and two antibodies (a partially selective for uPLB and b partially selective for pPLB), Eq. (1) 
Statistical analysis
Statistical analysis was performed using Origin 8.1. For validation of the method, the accuracies of X p and tPLB values, performed on known mixtures of standards, were calculated as X p (app)/X p and tPLB(app)/tPLB, so that 100% accuracy is given by a ratio of 1.00. Precision is expressed as the coefficient of variation (CV = standard deviation/mean). For analysis of true unknowns (pig CSR), values are reported as means ± standard errors of the mean (SEM), and one-way analysis of variance (ANOVA) was used to compare mean values, with a P value of less than 0.01 considered as significant. Exact values are reported for P P 0.01. Slope correlation coefficients (from linear regression) are expressed as Pearson's r.
Results
Densitometry for oligomeric forms of PLB
PLB has been shown to exist as a mixture of monomers and oligomers (mainly pentamers), in both native lipid bilayers and on SDS gels [16, 28, 41, 43, 44] , and oligomerization is enhanced by phosphorylation [28, 43] . It is essential to determine the effect of the PLB oligomeric state on quantitation by Western blot because it is entirely possible that an antibody would bind less effectively to the five protomers in a PLB pentamer than to the isolated monomer. Fortunately, it has been shown that heating PLB samples to 100°C in SDS solution just before electrophoresis, greatly decreases the extent of oligomerization observed on an SDS-PAGE gel and its subsequent Western blot [29] . Therefore, PLB standard curves were analyzed by Western blot with and without this preheating procedure (Fig. 1) . Heating substantially decreased the extent of PLB oligomerization, but there was no significant effect on the observed immunoblot intensity from any of the antibodies (Fig. 1) , clearly demonstrating that these immunoblot intensity values are independent of PLB's oligomeric state. Fig. 2 documents the accuracy and precision of our method. Each immunoblot (e.g., Fig. 2A ) contains a complete set of synthetic standards (both uPLB and pPLB) and ''unknown'' mixtures. Fig. 2B shows how the proportionality constants (e ij in Eq. (1)) are determined from standard curves, quantifying each antibody's sensitivity to uPLB and pPLB. For antibody a (Ab8A3, Ab2D12, or AbA1), e au > e ap , confirming that antibody a prefers to bind uPLB over pPLB. Conversely, antibody b (Ab285) greatly prefers to bind pPLB (e bu < e bp ) (Fig. 2B) . Fig. 2C and D show that the values of X p and tPLB, determined for the ''unknown'' mixtures from these blots using Eq. (4), are extremely accurate-no more than 10% error in all cases. One-way ANOVA showed no significant variation among the mean values for X p (app) or tPLB for any of the antibody pairs (Table 1 ). This high degree of both accuracy and precision is particularly remarkable in light of the large variability observed for the relative sensitivities of antibodies in separate blots (Table 2) . Thus, a key requirement of our method is that all standards and unknowns are run on each individual blot a and b.
Validation of methodology
Potential sources of systematic error
Lack of uPLB and pPLB standards and assumptions made about antibodies create systematic errors in tPLB and X p measurements. Without standards, accurate measurements cannot be made. When standards are used, Eq. (4) must be used to achieve accuracy without simplifying assumptions. For example, if it is assumed that antibody a reacts equally with uPLB and pPLB (e au = e ap ) in determination of tPLB, tPLB is underestimated in the presence of any pPLB, which leads to overestimation of X p (Fig. 3, method 1 ). If it is assumed that antibody a is completely specific for uPLB (e ap = 0), tPLB is systematically overestimated and X p is systematically underestimated (Fig. 3, method 2) . If it is assumed that antibody b (Ab285) is completely specific for pPLB (e bu = 0), tPLB and X p are both overestimated (Fig. 3, method 3 ). In the current method (Fig. 3, method   4 ), all e ij values were quantitatively included in calculations (Eq.
(4)). Our method returns X p and tPLB accurately, with all three choices of antibody a, whereas the systematic errors in methods 1-3 depend on the choice of antibody a (Fig. 3) due to different values of K UP (Table 2 ).
Application to pig CSR X p and tPLB were measured in CSR prepared from four different pigs (Fig. 4) . Standard curves were used to calculate proportionality constants e ij , and Eq. (4) was used to solve for X p and tPLB. Mixtures of synthetic standards were used as controls (X p control), yielding accurate values for X p and tPLB (data not shown), verifying the results of Fig. 2 . X p values were determined with high precision (SEM 6 0.01 for all four pig samples), but there was considerable variation among the four pigs, ranging from 0.08 ± 0.01 to 0.38 ± 0.01 (Fig. 4 and Table 3 ). Similarly, tPLB values were determined with high precision but varied widely among the four pigs, from 3.32 ± 0.01 to 13.0 ± 1.1 nmol/mg (Table 3) . Concordantly, ANOVA showed that both X p and tPLB showed statistically significant variation among the four pigs (Table 3) . However, a striking linear correlation between X p and tPLB was observed (Pearson's r = 0.99), such that CSR containing higher levels of tPLB also had a higher X p (Fig. 4B and Table 3 ).
We quantitated the SERCA content in the pig CSR samples using Coomassie stain (data not shown). Thus, we obtained the molar concentrations of SERCA, as well as those of tPLB, uPLB, and pPLB, in the four CSR samples. Combining these measurements, we determined the molar ratios of tPLB/SERCA, uPLB/SERCA, and pPLB/SERCA (Table 3 and Fig. 4C ). For all four samples, the tPLB/ SERCA ratio was consistently greater than 2 (as reported previously in rabbits and rats [36] ), and uPLB/SERCA was consistently greater than pPLB/SERCA. Both tPLB/SERCA and pPLB/SERCA showed statistically significant variation among the pigs (P < 0.01), but it is remarkable that uPLB/SERCA was essentially constant, showing no significant variation among the four pigs (P = 0.230) ( Table 3 Fig .1 . PLB oligomeric state does not affect immunoblot intensity. Typical immunoblots and standard curves are shown for samples preheated to 100°C (red) and unheated (blue) for uPLB (''u'' on blots, circles on graphs) or pPLB (''p'' on blots, squares on graphs) are shown for Ab285, Ab8A3, Ab2D12, and AbA1. Corresponding Western blots are above each graph. and Fig. 4C ). The calcium dependence of SERCA enzymatic activity was also found to be essentially invariant among the four pigs (Table 3 ).
Discussion
We have established an immunoblot method for the measurement of X p (the fraction of PLB that is phosphorylated at S16) and tPLB (the total PLB level). This method is extremely accurate (>96% for X p and >90% for tPLB, as shown in Fig. 2 and Table 1 ). The key to the accuracy of this method is the use of purified synthetic standards of uPLB and pPLB, along with antibodies that are partially selective for each, and rigorous calculations (Eq. (4)). Without these features, substantial systematic errors result (Fig. 3) .
When the method was applied to pig CSR obtained from different animals (Fig. 4) , the X p values were observed to be quite variable, ranging from 0.08 to 0.38 for four animals. Values of tPLB also varied widely, but there was a remarkably precise linear correlation between tPLB and X p (Fig. 4B) . We also measured SERCA content and used it to calculate PLB/SERCA ratios. Although pPLB/SERCA and tPLB/SERCA varied widely, there were no significant variations in uPLB/SERCA among the four pigs (Fig. 4 and Table 3 ). The regulation of SERCA by PLB, as indicated by calcium dependence of ATPase activity, was also invariant among the four pigs (Table 3 , pK Ca ).
Features of our method
The key features of our method are calibration within each immunoblot and a rigorously accurate calculation of X p and tPLB with Eq. (4), which combines two immunoblots. Calibration requires that both uPLB and pPLB standards of known concentration and phosphorylation state are available to generate standard curves and determine a unique set of proportionality constants for each blot. Due to variability of K UP among immunoblots (Table 2), standards and samples must be run on the same blot. To use Eq. (4) to calculate X p and tPLB reliably, the two blots (a and b) must have identical standards and unknowns, and blots a and b must be incubated with two antibodies with opposite selectivity for uPLB and pPLB.
If any of these features are missing, differences in antibody selectivity and sensitivity of isolated experiments introduce systematic errors into X p (app) and tPLB(app) calculations (Fig. 3) . Indeed, most measurements of PLB phosphorylation have lacked standards for uPLB and pPLB, so measurements were relative, inherently lacking accuracy [18, [45] [46] [47] [48] [49] [50] . For example, a sample that has 4 times more phosphorylation than a control may represent an increase from 0.03 to 0.12 (probably having little physiological effect) [16, 51] or from 0.25 to 1.00 (probably having a substantial physiological effect) [50] . There is only one study in the literature where standards of both uPLB and pPLB were used, along with a pair of antibodies with differential sensitivity, but that study did Table 1 Accuracy of X p and tPLB in known mixtures.
Ab8A3
Ab2D12 AbA1 ANOVA X p 0.98 ± 0.06 1.04 ± 0.04 1.05 ± 0.01 P = 0.98 tPLB 1.10 ± 0.03 1.07 ± 0.03 1.06 ± 0.05 P = 0.07
Note. Ab285 was used as the pPLB-selective antibody b. The uPLB-selective antibody a is given in the top row. Values in the second, third, and fourth columns indicate accuracy (apparent/actual) ± precision (CV = standard deviation/mean). P > 0.01 indicates no significant variation (n = 8 measurements for each value of X p for a total of 40). Note. K UP = e iu /e ip , where i = a or b. CV, coefficient of variation (=standard deviation/ mean). Primary antibody incubation times were varied from 1 to 2 h. not attempt quantitative calculations such as those in Eq. (4) [16] . Even with standards, Fig. 3 illustrates how assumptions about antibody selectivity can lead to systematic errors in determination of both tPLB and X p . This study focused on PLB phosphorylation at S16 because that site is more important physiologically than T17 [18] , due mainly to the lower level of phosphorylation at T17 [16] . Phosphorylation of PLB at T17 must be potentiated by S16 phosphorylation [52] , and T17 phosphorylation has a negligible effect on cardiac contractility after S16 has been phosphorylated [27] . Nevertheless, this method has the capacity to measure PLB phosphorylation at T17 using an antibody that is selective for T17-pPLB (commercially available from Santa Cruz Biotechnology, Santa Cruz, CA, USA, or from Badrilla, Leeds, UK) and a threonine-17-phosphorylated pPLB synthetic standard.
Application to biological membranes
We have used our method to make the first accurate measurements of X p and tPLB in biological samples. We found that the fraction of pPLB (X p ) in pig CSR is variable, ranging from 0.08 ± 0.01 to 0.38 ± 0.03 (Table 3) . Remarkably, even the greatest X p value was less than 0.5, leaving considerable reserve for response to b-adrenergic stimulation or response to phosphomimetic therapies [53] . The tPLB level was also quite variable, ranging from 3.32 ± 0.05 to 13.0 ± 1.13 nmol/mg total protein (Table 3) . Despite the wide variation in X p and tPLB among the pigs, the ratio of X p to tPLB was essentially constant (Fig. 4B) , suggesting that PLB phosphorylation increases to compensate for the inhibitory effects of high PLB expression. To further explore this hypothesis, we measured SERCA content in the same pig CSR samples and then calculated molar ratios tPLB/SERCA, uPLB/SERCA, and pPLB/SERCA (Table 3) . Differences in tPLB/SERCA, pPLB/SERCA, and X p all were statistically significant among the four pigs (P < 0.01), as was the difference in SERCA content (P < 0.01), but uPLB/SERCA did not vary significantly among the four pigs over a wide range of X p and SERCA measurements ( Fig. 4C and Table 3 ). Similarly, the calcium dependence of SERCA ATPase activity was essentially invariant (Table 3) . These results suggest that myocytes in nonfailing myocardium maintain SERCA activity by keeping uPLB/SERCA within a narrow range. Future studies are needed to test this hypothesis more rigorously. For example, freshly harvested tissue should be homogenized and analyzed quickly using phosphatase inhibitors to ensure that the phosphorylation status of PLB is captured accurately [46] .
Potential applications to research in physiology and pathology
Now that we can quantitate c u , c p , X p , tPLB, and SERCA with accuracy and precision, many questions concerning the role of PLB in cardiac function and pathology can be addressed more quantitatively. This method can standardize X p and tPLB measurements across studies even when the blots are performed in different laboratories, where the choice of primary antibodies and other experimental conditions may vary. The accuracy of our method will also normalize X p and tPLB values across animal systems, sample preparations, disease states, and therapies so that cross-study comparisons can be made. With this method in hand, it is possible to test the hypothesis that the uPLB/SERCA ratio increases in heart failure, resulting in decreased SERCA activity (increased pK Ca ) [27] . Thus, significant increases in uPLB/SERCA ratio may be a useful biomarker for heart disease and/or response to therapy in animal models of heart failure. The variation in X p and tPLB (Fig. 4) suggests that it is uPLB/SERCA that should be measured in these models, providing reference values for comparisons during diagnosis and over the course of treatment.
Potential clinical applications
Our method has potential for clinical applications, such as the assessment of changes in X p in human cardiac tissue in response to current treatments including b-adrenergic agonists, Ca 2+ channel blockers, phosphodiesterases, and future treatments in gene and drug therapy. Because milligram quantities of tissue are sufficient for replicate measurements of X p , tPLB, and uPLB/SERCA, it is plausible that human biopsies (1-2 mm 3 of tissue) [54] , which are performed routinely under suspicion of myocarditis, cardiomyopathy, or amyloidosis, can also be assayed for these values. Myocardial biopsy is a nonsurgical procedure with a complication rate of less than 1% to the patient [54] . Accurate tPLB calculations can also quantitatively determine changes in PLB expression, revealing factors that affect calcium regulation at the level of transcription or translation. Thus, our method can play an important role in evaluating the success of gene or drug therapies for heart failure. More generally, our approach can provide a quantitative measure of any protein modified by phosphorylation or with another posttranslational modification where (i) purified standards are available for both the unmodified and modified state of the protein and (ii) antibodies are available with differential sensitivity to the posttranslational modification.
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